Imperial College London - Pharmaceuticals & Healthcare - Deals and Alliances Profile
September 2018
91
About the Report
About the Report
Summary
Imperial College London (Imperial) is a research university that offers educational services. The university provides undergraduate and postgraduate courses. It offers courses in the field of science and technology, agriculture, business, the humanities, and medicine. It conducts clinical trials in the therapeutic areas of cancer, cardiovascular and diabetes, emergency and critical care, HIV and infectious disease, surgery and robotics, and others. Imperial's customized programs include finance, management, innovation and marketing, among others. The university offers collaborative research to promote connections between interests and research expertise. It also designs and conducts medical device trials. Imperial is headquartered in London, the UK.
Imperial College London-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Imperial College London, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Imperial College London, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Imperial College London, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Imperial College London, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Imperial College London, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Imperial College London, Medical Devices Deals, 2012 to YTD 2018 10
Imperial College London, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Imperial College London, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Boehringer Ingelheim, Imperial College London, University of Oxford, University of Edinburgh, Imperial Innovations, and Oxford BioMedica Enter into Collaboration Agreement 13
Evgen Pharma Enters into Agreement with Imperial College London 15
Heptares Therapeutics Enters into Research Agreement with Imperial College London 16
AstraZeneca and Imperial College London Enter into Research Partnership 17
Natera Enters into Agreement with Imperial College London and University of Leicester 18
Smith & Nephew Enters into Agreement with Imperial College London 19
Optibrium Enters into Partnership with Imperial College London and DNDi 20
Domainex Expands its Agreement with Imperial College London 21
Protectimmun Enters into Research Agreement with Janssen Biotech And Imperial College 22
Cambridge University, Imperial College London, King's College London, Queen Mary University London, University College London and Oxford University Enter into Research and Development Agreement with Pfizer 23
Prosonix Enters Into Research Agreement With Imperial College London 25
UCB Enters Into Co-Development Agreement With Imperial College London 26
Imperial College London-Key Competitors 27
Imperial College London-Key Employees 28
Imperial College London-Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Joint Venture 29
Recent Developments 30
Government and Public Interest 30
Sep 03, 2018: Ground-breaking approach accelerates drug discovery process 30
Aug 26, 2018: Blood pressure medications and statins found to provide long-term cardiovascular benefits 31
Aug 26, 2018: Long-term cardiovascular benefits following statins and blood pressure trial 32
Aug 13, 2018: Ovarian cancer genetics unravelled 34
Jul 30, 2018: Liver cancer cell 'switch' found that could improve future therapies 36
Jul 25, 2018: Glaucoma hope from turmeric eye drops 37
Jul 24, 2018: First randomised trial of 'kick and kill' approach to HIV cure leaves puzzles to be solved 39
Jul 17, 2018: Allergic responses linked to skin cancer protection and Toxin Hypothesis 40
Jun 28, 2018: Financial incentives help to drive down unnecessary antibiotic prescribing 42
Jun 27, 2018: Cancer-causing virus HTLV-1 changes DNA loops, affecting thousands of genes 44
Jun 26, 2018: Genes and personalised medicine will tackle life-threatening heart condition 46
Jun 25, 2018: Gut bacteria may help detect liver disease early 47
Jun 21, 2018: New insights into DNA 'melting' reveal chink in bacteria's armour 48
Jun 11, 2018: Experts explain how personalised diabetes treatments can help patients 49
Jun 06, 2018: Funding boost for Imperial researchers aiming to stop bowel cancer 50
Jun 04, 2018: EUR10m project to tackle Europe's childhood obesity launches at Imperial 51
Apr 30, 2018: Imperial College and Pulmocide demonstrates the relationship between RSV viral load and immune biomarkers using a novel, minimally invasive sampling procedure from the nose of infants with RSV bronchiolitis. 52
Apr 27, 2018: Scientists join forces to fight TB and HIV in EUR 12.9 million TREATS trial 53
Apr 24, 2018: Early treatment for leg ulcers gets patients back on their feet 54
Mar 27, 2018: Reading of biological molecules improved up to 100x by doubling the sensors 56
Feb 14, 2018: Organ-on-chip technology enters next stage as experts test hepatitis B virus 57
Jan 30, 2018: International project launches to prevent stroke in patients with brain bleeding 58
Jan 30, 2018: A research team of Professor Philippe Froguel discovers a new gene responsible for childhood obesity 59
Jan 26, 2018: Type 2 diabetics at increased risk of dementia, study suggests 60
Jan 22, 2018: Industrial Strategy boost for UK medicines with GBP70 million of funding to help develop new treatments 61
Jan 05, 2018: Glucose in the airways could increase infections in lung disease patients 63
Dec 21, 2017: Leukaemia treatment can be made more effective by using a drug for iron overload 65
Dec 12, 2017: Ultra-thin tissue samples could help to understand and treat heart disease 66
Dec 05, 2017: Birth control for parasites: researchers reveal new vaccine target for malaria 67
Nov 30, 2017: New wave of European Research Council grants won by Imperial researchers 68
Nov 23, 2017: Promising new treatment for rare pregnancy cancer leads to remission in patients 70
Nov 15, 2017: Signalling protein found to drive heart scarring and organ failure 73
Oct 31, 2017: Revisiting abandoned treatments in fight against antimicrobial-resistant gonorrhea 74
Sep 25, 2017: Human antibodies from dengue patients can effectively treat Zika infection in mice 75
Sep 25, 2017: Antibody protects against both Zika and dengue, mouse study shows 77
Sep 06, 2017: Scientists link 153 new genetic variants to osteoporosis in largest ever study 79
May 12, 2017: A lead candidate for immunotherapy may increase tumour growth in certain cancers 80
Mar 17, 2017: Molecular therapy set to protect at-risk patients against heart attack and stroke 82
Mar 17, 2017: Molecular Therapy Aims to Protect High-risk Patients From Heart Attacks and Strokes 83
Feb 07, 2017: Researchers find that non-coding RNA regulates the expression of key genes in diabetes 84
Product News 85
May 14, 2018: Molecule that acts on human cells might provide hope for irresistible cold cure 85
Apr 30, 2018: Vodafone Foundation and Imperial College London launch groundbreaking new crowdsourcing app to speed up cancer research 86
Jan 10, 2018: 3D printing creates super-soft structures that replicate brain and lungs 87
Other Significant Developments 88
Jul 05, 2018: Prostate cancer ultrasound treatment as effective as surgery or radiotherapy 88
Nov 08, 2017: NPL and Imperial College London Launch a New Virtual Lab to Establish the UK Centre for Engineering Biology, Metrology and Standards 90
Appendix 91
Methodology 91
About GlobalData 91
Contact Us 91
Disclaimer 91
List of Figure
List of Figures
Imperial College London, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Imperial College London, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Imperial College London, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Imperial College London, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Imperial College London, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Imperial College London, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Imperial College London, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Imperial College London, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Imperial College London, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Imperial College London, Pharmaceuticals & Healthcare, Key Facts 2
Imperial College London, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Imperial College London, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Imperial College London, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Imperial College London, Deals By Therapy Area, 2012 to YTD 2018 9
Imperial College London, Medical Devices Deals, 2012 to YTD 2018 10
Imperial College London, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Boehringer Ingelheim, Imperial College London, University of Oxford, University of Edinburgh, Imperial Innovations, and Oxford BioMedica Enter into Collaboration Agreement 13
Evgen Pharma Enters into Agreement with Imperial College London 15
Heptares Therapeutics Enters into Research Agreement with Imperial College London 16
AstraZeneca and Imperial College London Enter into Research Partnership 17
Natera Enters into Agreement with Imperial College London and University of Leicester 18
Smith & Nephew Enters into Agreement with Imperial College London 19
Optibrium Enters into Partnership with Imperial College London and DNDi 20
Domainex Expands its Agreement with Imperial College London 21
Protectimmun Enters into Research Agreement with Janssen Biotech And Imperial College 22
Cambridge University, Imperial College London, King's College London, Queen Mary University London, University College London and Oxford University Enter into Research and Development Agreement with Pfizer 23
Prosonix Enters Into Research Agreement With Imperial College London 25
UCB Enters Into Co-Development Agreement With Imperial College London 26
Imperial College London, Key Competitors 27
Imperial College London, Key Employees 28
Imperial College London, Subsidiaries 29
Imperial College London, Joint Venture 29
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.